Department of Thoracic Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Second Department of Thoracic Surgery, Chest Hospital of Xinjiang, Urumqi, China.
Ann Thorac Surg. 2018 Jul;106(1):257-263. doi: 10.1016/j.athoracsur.2018.02.009. Epub 2018 Mar 9.
Resection is an effective treatment for thymic carcinoma. We aimed to develop a nomogram for postoperative prediction of recurrence-free survival for patients with thymic carcinoma and guide adjuvant radiotherapy.
A total of 198 patients who underwent surgery were divided into training cohort (n = 152) and validation cohort (n = 46). Clinicopathologic features and independent factors for postoperative recurrence were analyzed. A predictive nomogram was developed based on the prognostic factors. Discrimination and predictive accuracy of the model were measured using the concordance index (C-index), calibration curves, and validation study.
The overall 1-, 3-, and 5-year recurrence rate of 198 patients was 7.6%, 27.9%, and 39.9%, respectively. Independent predictors of recurrence-free survival on multivariate analysis were incorporated into the nomogram. Calibration curves for the probability of 1-, 3-, and 5-year recurrence-free survival fitted well. The C-index of the nomogram for predicting recurrence-free survival was 0.862 (95% confidence interval: 0.804 to 0.919). Internal validation supported the results optimally. Adjuvant radiotherapy was effective for patients with a total score greater than 208.
Our nomogram for predicting recurrence-free survival had good performance. Adjuvant radiotherapy should be recommended for patients with a total score greater than 208.
切除术是治疗胸腺癌的有效方法。我们旨在为胸腺癌患者建立一种用于预测术后无复发生存率的列线图,并指导辅助放疗。
对 198 例接受手术治疗的患者进行分析,将其分为训练队列(n=152)和验证队列(n=46)。分析了临床病理特征和术后复发的独立因素。基于预后因素,建立了预测列线图。采用一致性指数(C 指数)、校准曲线和验证研究来评估模型的区分度和预测准确性。
198 例患者的总体 1 年、3 年和 5 年复发率分别为 7.6%、27.9%和 39.9%。多因素分析的独立预测因素被纳入列线图。1 年、3 年和 5 年无复发生存率的校准曲线拟合良好。预测无复发生存率的列线图 C 指数为 0.862(95%置信区间:0.804 至 0.919)。内部验证最佳地支持了结果。总分为 208 分以上的患者辅助放疗有效。
我们预测无复发生存率的列线图具有良好的性能。总分为 208 分以上的患者应推荐进行辅助放疗。